Cytori Cell Research Institute, Inc.

Tokyo Stock Exchange 3750.T

Cytori Cell Research Institute, Inc. Net Cash Used Provided By Financing Activities for the year ending March 31, 2024: USD -47.39 M

Cytori Cell Research Institute, Inc. Net Cash Used Provided By Financing Activities is USD -47.39 M for the year ending March 31, 2024, a -2,239.81% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.
  • Cytori Cell Research Institute, Inc. Net Cash Used Provided By Financing Activities for the year ending March 31, 2023 was USD 2.21 M, a 653.10% change year over year.
  • Cytori Cell Research Institute, Inc. Net Cash Used Provided By Financing Activities for the year ending March 31, 2022 was USD 294.07 K, a -78.38% change year over year.
  • Cytori Cell Research Institute, Inc. Net Cash Used Provided By Financing Activities for the year ending March 31, 2021 was USD 1.36 M, a -97.70% change year over year.
  • Cytori Cell Research Institute, Inc. Net Cash Used Provided By Financing Activities for the year ending March 31, 2020 was USD 59.12 M.
Key data
Date Net Cash Used Provided By Financing Activities Dividends Paid Capital Expenditure Effect Of Forex Changes On Cash
Market news
SV Wall Street
Tokyo Stock Exchange: 3750.T

Cytori Cell Research Institute, Inc.

CEO Mr. Yoshihiro Hoshino
IPO Date Jan. 1, 2001
Location Japan
Headquarters Otemachi Park Building, 1-1-1 Otemachi
Employees 16
Sector Health Care
Industries
Biotechnology Clinical Trials Pharmaceuticals
Description

Cytori Cell Research Institute, Inc., engages in the research, development, production, and sale of cell therapy related medical devices in Japan. The company sells cell therapy kits, as well as engages in the research and development of cell therapy technology, etc. Its products pipeline includes ECCI-50 for the treatment of male stress urinary incontinence and liver cirrhosis; and Cyt-006 to prevent postoperative adhesion for primary rectal cancer. The company is also conducting clinical trials/research on cell therapy for a range of diseases and applications, including anterior cruciate ligament repair, bone repair, burn scars, chronic wound healing, critical limb ischemia, anal and Crohn's disease fistulas, erectile dysfunction, etc. It also invests in, owns, develops, leases, and manages real estate projects and hotels; and provides real estate brokerage services. The company was formerly known as FRACTALE Corporation. Cytori Cell Research Institute, Inc. was incorporated in 2004 and is headquartered in Tokyo, Japan.

StockViz Staff

February 8, 2025

Any question? Send us an email